跳到主要內容

臺灣博碩士論文加值系統

(18.206.76.226) 您好!臺灣時間:2021/07/30 23:18
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:蕭君平
研究生(外文):SHIAU, JUN-PING
論文名稱:較晚啟動輔助性化學治療對早期乳癌患者預後的影響:台灣癌症資料庫的分析結果
論文名稱(外文):Impact of delayed initiation of adjuvant chemotherapy in early breast cancer: analysis from Taiwan Cancer Registry Database
指導教授:侯明鋒侯明鋒引用關係
指導教授(外文):HOU, MING-FENG
口試委員:侯明鋒郭耀隆潘美仁
口試委員(外文):HOU, MING-FENGKUO, YAO-LUNGPAN, MEI-REN
口試日期:2021-05-17
學位類別:碩士
校院名稱:高雄醫學大學
系所名稱:臨床醫學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2021
畢業學年度:109
語文別:英文
論文頁數:54
中文關鍵詞:乳癌輔助性化學治療總體存活率無局部復發存活率無遠端復發存活率
外文關鍵詞:breast canceradjuvant chemotherapyoverall survivallocal-regional free survivaldistant-free survival
ORCID或ResearchGate:orcid.org/0000-0003-0443-962X
相關次數:
  • 被引用被引用:0
  • 點閱點閱:8
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
1. Abstract and Keywords……………………………………………………………………………………………………………………………………4
2. Introduction……………………………………………………………………………………………………………………………………………………………6
3. Material and Method
3.1 Material description……………………………………………………………………………………………………………………………………8
3.2 Statistical analysis method…………………………………………………………………………………………………………………9
4. Results
4.1 Patient demography…………………………………………………………………………………………………………………………………………11
4.2 Subgroup distribution…………………………………………………………………………………………………………………………………12
4.3 TTCI comparison in clinicopathological factor…………………………………………………………………12
4.4 Univariable cox regression analysis of overall survival………………………………………13
4.5 Multivariable cox regression analysis of overall survival…………………………………15
4.6 Kaplan-Meier plot of all patient group……………………………………………………………………………………16
4.7 Kaplan-Meier plot of subgroup……………………………………………………………………………………………………………17
4.8 Delayed TACI impaction of HR in OS and RFS…………………………………………………………………………18
4.9 HR of delayed TACI on OS in different subtypes ……………………………………………………………18
5. Discussion
5.1 Definition of TACI ………………………………………………………………………………………………………………………………………19
5.2 Interval classification of TACI………………………………………………………………………………………………………20
5.3 Waiting time between surgery and adjuvant chemotherapy ………………………………………21
5.4 Taiwan National Health insurance and breast cancer …………………………………………………22
5.5 Adjuvant chemotherapy regimens ………………………………………………………………………………………………………23
5.6 OS and CSS ……………………………………………………………………………………………………………………………………………………………24
5.7 Limitation ……………………………………………………………………………………………………………………………………………………………24
6. Conclusion ………………………………………………………………………………………………………………………………………………………………26
7. Acknowledgement……………………………………………………………………………………………………………………………………………………26
8. Tables
Table 1…………………………………………………………………………………………………………………………………………………………………………………27
Table 2…………………………………………………………………………………………………………………………………………………………………………………30
Table 3…………………………………………………………………………………………………………………………………………………………………………………31
Table 4…………………………………………………………………………………………………………………………………………………………………………………33
Table 5…………………………………………………………………………………………………………………………………………………………………………………35
Table 6…………………………………………………………………………………………………………………………………………………………………………………36
9. Figures
Figure 1………………………………………………………………………………………………………………………………………………………………………………37
Figure 2………………………………………………………………………………………………………………………………………………………………………………39
10. Reference…………………………………………………………………………………………………………………………………………………………………41

1.Siegel, R.L., K.D. Miller, and A. Jemal, Cancer Statistics, 2017. CA Cancer J Clin, 2017. 67(1): p. 7-30.
2.National Cancer Institute, U. Surveillance, Epidermiology, and End Result Program; Cancer Stat Facts: Female Breast Cancer. [cited 2021 05/31]; Available from: https://seer.cancer.gov/statfacts/html/breast.html.
3.Ashok Kumar, P., et al., Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study. J Cancer Res Clin Oncol, 2021: p. 1-12.
4.Biagi, J.J., et al., Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. Jama, 2011. 305(22): p. 2335-42.
5.Booth, C.M., et al., Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study. Cancer, 2013. 119(6): p. 1243-50.
6.Lu, H., et al., Does delayed initiation of adjuvant chemotherapy following the curative resection affect the survival outcome of gastric cancer patients: A systematic review and meta-analysis. Eur J Surg Oncol, 2020. 46(6): p. 1103-1110.
7.Dai, X., et al., Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer, 2016. 7(10): p. 1281-94.
8.Grann, V.R., et al., Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer, 2005. 103(11): p. 2241-51.
9.Dunnwald, L.K., M.A. Rossing, and C.I. Li, Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res, 2007. 9(1): p. R6.
10.Howlader, N., et al., US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst, 2014. 106(5).
11.Raphael, M.J., et al., The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat, 2016. 160(1): p. 17-28.
12.Cold, S., et al., Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer, 2005. 93(6): p. 627-32.
13.Shannon, C., S. Ashley, and I.E. Smith, Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol, 2003. 21(20): p. 3792-7.
14.Chavez-MacGregor, M., et al., Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. JAMA Oncol, 2016. 2(3): p. 322-9.
15.Zhan, Q.H., et al., Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis. Oncotarget, 2018. 9(2): p. 2739-2751.
16.Gagliato Dde, M., et al., Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol, 2014. 32(8): p. 735-44.
17.Lohrisch, C., et al., Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol, 2006. 24(30): p. 4888-94.
18.Kupstas, A.R., et al., Effect of Surgery Type on Time to Adjuvant Chemotherapy and Impact of Delay on Breast Cancer Survival: A National Cancer Database Analysis. Ann Surg Oncol, 2019. 26(10): p. 3240-3249.
19.Health Insurance Information Opening Service, T. [cited 2021 05/31]; Available from: https://data.nhi.gov.tw/Datasets/DatasetList.aspx?c=72.
20.Chiang, C.J., et al., Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol, 2015. 45(3): p. 291-6.
21.Downing, A., et al., Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. Breast J, 2014. 20(1): p. 29-36.
22.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005. 365(9472): p. 1687-717.
23.Bleicher, R.J., et al., Time to Surgery and Breast Cancer Survival in the United States. JAMA Oncol, 2016. 2(3): p. 330-9.
24.Peto, R., et al., Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 2012. 379(9814): p. 432-44.
25.Gunduz, N., B. Fisher, and E.A. Saffer, Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res, 1979. 39(10): p. 3861-5.
26.O'Reilly, M.S., et al., Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997. 88(2): p. 277-85.
27.O'Reilly, M.S., et al., Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 1994. 79(2): p. 315-28.
28.Fisher, B., et al., Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res, 1989. 49(8): p. 1996-2001.
29.Heppner, G.H., In vitro studies on cell-mediated immunity following surgery in mice sensitized to syngeneic mammary tumors. Int J Cancer, 1972. 9(1): p. 119-25.
30.Schmidt, M., Chemotherapy in early breast cancer: when, how and which one? Breast Care (Basel), 2014. 9(3): p. 154-60.
31.Yu, K.D., et al., Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer, 2013. 13: p. 240.
32.Farolfi, A., et al., Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer, 2015. 51(14): p. 1874-81.
33.Alkis, N., et al., Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol, 2011. 28(4): p. 1255-9.
34.Seneviratne, S., et al., Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study. BMC Cancer, 2014. 14: p. 839.
35.Buzdar, A.U., et al., Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat, 1982. 2(2): p. 163-9.
36.Jara Sánchez, C., et al., Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat, 2007. 101(2): p. 215-23.
37.Nurgalieva, Z.Z., et al., Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol, 2013. 30(1): p. 419.
38.Hershman, D.L., et al., Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat, 2006. 99(3): p. 313-21.
39.Network, N.C.C. Bresat Cancer (Version 3.2021). April 25, 2021]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
40.Zeleke Alem, A., E. Gebeye Zeleke, and T.Y. Akalu, Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study. Breast Cancer (Dove Med Press), 2020. 12: p. 97-108.
41.Services, D.o.H.a.H. Center for medicare and medicaid services. 2014 [cited 2021 April 10]; 42 CFR Parts 405, 412, 413, 415, 422, 424, 485 and 488.]. Available from: https ://www.govin fo.gov/conte nt/pkg/FR-2014-08-22/pdf/2014-18545 .pdf.
42.Losk, K., et al., Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center. J Natl Compr Canc Netw, 2016. 14(12): p. 1519-1526.
43.Gluz, O., et al., Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol, 2016. 27(6): p. 1035-1040.
44.Jones, S., et al., Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol, 2009. 27(8): p. 1177-83.
45.Jones, S.E., et al., Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol, 2006. 24(34): p. 5381-7.
46.Fujii, T., et al., Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol, 2015. 1(9): p. 1311-8.


電子全文 電子全文(網際網路公開日期:20230101)
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top